Cardiovascular imaging accounts for 30 percent of all the radiation patients receive in the U.S. and today, at the Society for Nuclear Medicine annual meeting, Spectrum Dynamics announced it has begun clinical studies to show that its D-SPECT™ technology can accommodate significantly lower doses of radiopharmaceutical agents so the total radiation exposure to patients and staff is much lower compared to conventional cardiac imaging.
Spectrum Dynamics is conducting two different ultra low dose trials with Columbia University in New York and Cardiovascular Imaging Technologies (CVIT) in Kansas City. They are expected to be published later this year or early in 2011.
Leader of the Columbia study is Andrew Einstein, MD, cardiologist and assistant professor of clinical medicine at Columbia's College of Physicians and Surgeons in New York. Speaking at a symposium at the American College of Cardiology annual conference in March, Dr. Einstein said current radiation doses used in cardiovascular imaging are "a problem for patients, a problem for populations, and problem for the profession. At the doses that our patients receive, there is the potential for increased risk for cancer and that's why we are concerned," he said.
In previous studies, the D-SPECT technology has demonstrated unique capability to drastically reduce imaging time which, in turn, allows for ultra-low dosing of the radiopharmaceutical agents required to perform myocardial perfusion imaging.